An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TARGET3D
- 16 Nov 2017 Status changed from active, no longer recruiting to recruiting.
- 24 Oct 2017 Results (n=30) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 10 Jun 2017 Biomarkers information updated